Conference on HIV Science (IAS 2025) concluded in Kigali after five dynamic days (July 13-17), delegates left with a mix of hope and concern--buoyed by scientific breakthroughs but unsettled by a ...

Participants who initiated long-acting cabotegravir-rilpivirine had a high rate of adherence and virologic suppression, with ...

The program known as PEPFAR is one of the most effective and popular U.S. foreign aid projects in history, and the government ...

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the ...

Two monoclonal antibodies appeared safe and tolerable when administered alone or in combination to newborns exposed to HIV, according to a proof-of-concept study presented at the International AIDS ...

South Africa has the world’s largest HIV treatment programme, with over 5. 5 million people receiving antiretrovirals (ARVs).

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th ...

Researchers wanted to provide insight into the relative clinical value of Apretude and lenacapavir compared with no ...

For more than two decades, the global community has united to fight the HIV pandemic, achieving remarkable progress. New HIV transmissions and AIDS-related deaths have dropped significantly, and ...

The temporary suspension of PEPFAR has disrupted preventive treatments, infant testing, and the work of community health ...